In a bid to combat the rising threat of antibacterial resistance, researchers from the Research Center for Biomass and Bioproducts, National Research and Innovation Agency (BRIN), have delved into the characteristics and applications of biomass-derived antibacterial agents.
Apellis’ C3 inhibitor shows biomarker impact in small PhII rare kidney disease trial
Apellis Pharmaceutical’s pegcetacoplan has shown hints of efficacy in a handful of patients with rare kidney diseases in a Phase II trial, five months after
October 18, 2023